Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
Jade Biosciences has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Jade Biosciences's investors include Franklin Templeton, RA Capital Management, Samsara BioCapital, Janus Henderson Investors, Venrock.
Jade Biosciences is headquartered in Waltham, United States.
Jade Biosciences is developing transformative therapies to redefine the standard of care for inflammation and immunology indications.
Jade Biosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Jade Biosciences — Funding & Investors." VCBacked, June 3, 2026, https://www.vcbacked.co/company/jade-biosciences. Accessed July 19, 2026.
VCBacked. (2026). Jade Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/jade-biosciences
{{cite web |title=Jade Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/jade-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated